Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) has granted 58,300 restricted stock units (RSUs) to ten new employees under its 2017 Inducement Equity Incentive Plan on February 11, 2025. The RSUs will vest 25% after one year, with the remaining 75% vesting in twelve equal quarterly installments, subject to continued employment.
The grants are specifically designed as employment inducements for new hires who were not previously associated with Esperion, in compliance with NASDAQ Listing Rule 5635(c)(4). Esperion is a commercial-stage biopharmaceutical company that develops and commercializes FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients.
Esperion (NASDAQ: ESPR) ha concesso 58.300 unità di azioni riservate (RSU) a dieci nuovi dipendenti nell'ambito del suo Piano di Incentivazione Azionaria 2017 il 11 febbraio 2025. Le RSU matureranno il 25% dopo un anno, con il restante 75% che maturerà in dodici rate trimestrali uguali, a condizione di continuare l'impiego.
Le concessioni sono specificamente progettate come incentivi all'occupazione per i nuovi assunti che non erano precedentemente associati a Esperion, in conformità con la Regola di Quotazione NASDAQ 5635(c)(4). Esperion è un'azienda biofarmaceutica in fase commerciale che sviluppa e commercializza farmaci orali approvati dalla FDA, da assumere una volta al giorno, non statinici, per pazienti con malattie cardiovascolari e livelli elevati di LDL-C. I loro farmaci sono supportati dallo studio CLEAR Cardiovascular Outcomes che coinvolge quasi 14.000 pazienti.
Esperion (NASDAQ: ESPR) ha otorgado 58,300 unidades de acciones restringidas (RSUs) a diez nuevos empleados bajo su Plan de Incentivo de Capital de 2017 el 11 de febrero de 2025. Las RSUs se consolidarán en un 25% después de un año, con el 75% restante consolidándose en doce cuotas trimestrales iguales, sujeto a la continuidad del empleo.
Las concesiones están diseñadas específicamente como incentivos de empleo para nuevos contratados que no estaban previamente asociados con Esperion, en cumplimiento con la Regla de Cotización NASDAQ 5635(c)(4). Esperion es una compañía biofarmacéutica en fase comercial que desarrolla y comercializa medicamentos orales aprobados por la FDA, que se toman una vez al día y que no son estatinas, para pacientes con enfermedades cardiovasculares y niveles elevados de LDL-C. Sus medicamentos están respaldados por el estudio CLEAR Cardiovascular Outcomes que involucra a casi 14,000 pacientes.
에스페리온 (NASDAQ: ESPR)은 2025년 2월 11일 2017년 유도 주식 인센티브 계획에 따라 10명의 신규 직원에게 58,300개의 제한 주식 단위(RSU)를 부여했습니다. RSU는 1년 후에 25%가 확정되며, 나머지 75%는 계속 근무하는 조건 하에 12회의 동일한 분기별 할부로 확정됩니다.
이번 부여는 에스페리온과 이전에 연결되지 않았던 신규 채용을 위한 고용 유도책으로 특별히 설계되었으며, NASDAQ 상장 규칙 5635(c)(4)를 준수합니다. 에스페리온은 심혈관 질환 및 높은 LDL-C 환자를 위한 FDA 승인 경구용 비스타틴 의약품을 개발하고 상용화하는 상업 단계의 생물 제약 회사입니다. 그들의 약물은 거의 14,000명의 환자가 참여한 CLEAR 심혈관 결과 시험의 지원을 받고 있습니다.
Esperion (NASDAQ: ESPR) a accordé 58 300 unités d'actions restreintes (RSUs) à dix nouveaux employés dans le cadre de son Plan d'Incentive Équity de 2017 le 11 février 2025. Les RSUs seront acquises à 25 % après un an, le reste de 75 % étant acquis en douze versements trimestriels égaux, sous réserve de la poursuite de l'emploi.
Les attributions sont spécifiquement conçues comme des incitations à l'emploi pour les nouvelles recrues qui n'étaient pas auparavant associées à Esperion, en conformité avec la Règle de Cotation NASDAQ 5635(c)(4). Esperion est une entreprise biopharmaceutique en phase commerciale qui développe et commercialise des médicaments oraux, approuvés par la FDA, à prendre une fois par jour, non statiniques, pour les patients atteints de maladies cardiovasculaires et de niveaux élevés de LDL-C. Leurs médicaments sont soutenus par l'étude CLEAR Cardiovascular Outcomes impliquant près de 14 000 patients.
Esperion (NASDAQ: ESPR) hat am 11. Februar 2025 58.300 eingeschränkte Aktieneinheiten (RSUs) an zehn neue Mitarbeiter im Rahmen seines Anreizaktienplans von 2017 gewährt. Die RSUs werden nach einem Jahr zu 25% fällig, während die verbleibenden 75% in zwölf gleichen vierteljährlichen Raten fällig werden, vorbehaltlich der Fortsetzung der Beschäftigung.
Die Gewährungen sind speziell als Beschäftigungsanreize für neue Mitarbeiter konzipiert, die zuvor nicht mit Esperion verbunden waren, in Übereinstimmung mit der NASDAQ-Listing-Regel 5635(c)(4). Esperion ist ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das FDA-zugelassene orale, einmal täglich einzunehmende, nicht-statinische Medikamente für Patienten mit Herz-Kreislauf-Erkrankungen und erhöhtem LDL-C entwickelt und vermarktet. Ihre Medikamente werden durch die CLEAR Cardiovascular Outcomes-Studie unterstützt, an der fast 14.000 Patienten beteiligt sind.
- Company is expanding workforce with 10 new hires
- Has FDA-approved oral medications in commercial stage
- Maintains large-scale clinical validation with 14,000-patient CLEAR trial
- Stock dilution through new RSU grants to employees
ANN ARBOR, Mich., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on February 11, 2025, the Company granted ten new employees 58,300 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan.
The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
Each RSU will vest and become exercisable as to 25 percent of the shares on the one-year anniversary of the recipient’s vesting commencement date and will vest and become exercisable as to the remaining 75 percent of the shares in twelve equal quarterly installments at the end of each quarter following such anniversary, in each case, subject to each such employee's continued employment with Esperion on such vesting dates. The RSUs are subject to the terms and conditions of Esperion’s 2017 Inducement Equity Incentive Plan, and the terms and conditions of the RSU agreement covering the grant.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and esperionscience.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
How many RSUs did Esperion (ESPR) grant to new employees in February 2025?
What is the vesting schedule for Esperion's February 2025 RSU grants?
Why did Esperion (ESPR) issue these RSU grants in February 2025?
What type of medications does Esperion (ESPR) currently commercialize?
